Scholarlink

Background <p>Idiopathic REM sleep behavior disorder (iRBD) indicates an early α-synucleinopathy, offering a window for early detection and intervention.</p> Objective <p>Explore a serum-based biomarker panel, comprising NfL, GFAP, t-tau, and UCH-L1, in patients with iRBD, and compare to individuals with synucleinopathy and healthy controls.</p> Method <p>This is a cross-sectional, observational study. Serum biomarkers were measured using the single molecule array technique. Clinical evaluation included standardized assessments of sleep, cognitive function, motor symptoms, and psychiatric features.</p> Results <p>GFAP levels were significantly higher in the iRBD group than in the control and synucleinopathy groups. Serum NfL levels yielded conflicting results. T-tau and UCHL-1 protein levels were lower in the iRBD and synucleinopathy groups compared to the control group.</p> Conclusion <p>Our findings suggest that serum levels of NfL, GFAP, t-tau, and UCH-L1 may serve as potential biomarkers in iRBD, primarily GFAP levels.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Exploratory serum biomarker profiling in idiopathic REM sleep behavior disorder: evidence of early neurodegenerative signatures: a pilot study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月11日

查看全文
  • Danielle Mesquita Torres,
  • Fábio Henrique Queiroz Pereira,
  • Marylane da Silva Viana,
  • Mariana Michilles Santos Ramos,
  • Elisa Gabriela Barros Cunha,
  • Leonardo José Rodrigues de Araújo Melo,
  • Emmanuelle Silva Tavares Sobreira,
  • Francisca Charliane Almino Lopes,
  • Annyta Fernandes Frota,
  • Michelle Verde Ramos Soares,
  • Ricardo Titze- de- Almeida,
  • Pedro Braga-Neto,
  • Danielle S. Macedo,
  • Manoel Alves Sobreira-Neto

摘要

Background

Idiopathic REM sleep behavior disorder (iRBD) indicates an early α-synucleinopathy, offering a window for early detection and intervention.

Objective

Explore a serum-based biomarker panel, comprising NfL, GFAP, t-tau, and UCH-L1, in patients with iRBD, and compare to individuals with synucleinopathy and healthy controls.

Method

This is a cross-sectional, observational study. Serum biomarkers were measured using the single molecule array technique. Clinical evaluation included standardized assessments of sleep, cognitive function, motor symptoms, and psychiatric features.

Results

GFAP levels were significantly higher in the iRBD group than in the control and synucleinopathy groups. Serum NfL levels yielded conflicting results. T-tau and UCHL-1 protein levels were lower in the iRBD and synucleinopathy groups compared to the control group.

Conclusion

Our findings suggest that serum levels of NfL, GFAP, t-tau, and UCH-L1 may serve as potential biomarkers in iRBD, primarily GFAP levels.